Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11191771 Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors

Patent 11191771 was granted and assigned to SeaGen on December, 2021 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

SeaGen

Current Assignee

SeaGen

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

111917710

Patent Inventor Names

Rory Rohm0

Robert Thurman0

Travis Biechele0

William Arthur0

Date of Patent

December 7, 2021

Patent Application Number

163082250

Date Filed

June 8, 2017

Patent Citations Received

‌

US Patent 11945785 Pyrazine compounds as inhibitors of FLT3

Patent Primary Examiner

‌

Sheela J. Huff

Patent abstract

This invention relates to treatment of cancer using a antibody drug conjugates that comprise PBD molecules in combination with FLT3 inhibitors.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11191771 Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API